drugset / Trial / NCT02536300
Dose Optimization Study of Idelalisib in Follicular Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
Timeline
- Start
- 2016-01-14
- Primary completion
- 2022-09-27
- Completion
- 2022-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | 100 mg | Oral |
| Subject | Idelalisib | Small molecule | 150 mg | Oral |